Alpha Geek

(8)

$10/per page/Negotiable

About Alpha Geek

Levels Tought:
University

Expertise:
Accounting,Algebra See all
Accounting,Algebra,Architecture and Design,Art & Design,Biology,Business & Finance,Calculus,Chemistry,Communications,Computer Science,Environmental science,Essay writing,Programming,Social Science,Statistics Hide all
Teaching Since: Apr 2017
Last Sign in: 438 Weeks Ago, 2 Days Ago
Questions Answered: 9562
Tutorials Posted: 9559

Education

  • bachelor in business administration
    Polytechnic State University Sanluis
    Jan-2006 - Nov-2010

  • CPA
    Polytechnic State University
    Jan-2012 - Nov-2016

Experience

  • Professor
    Harvard Square Academy (HS2)
    Mar-2012 - Present

Category > Accounting Posted 04 Jun 2017 My Price 8.00

PREPARING A STATEMENT OF CASH FLOWS FROM BALANCE SHEETS AND INCOME STATEMENTS

3.23     PREPARING A STATEMENT OF CASH FLOWS FROM BALANCE SHEETS AND INCOME STATEMENTS. Fuso Pharmaceutical Industries develops, manufactures, and markets pharmaceutical products in Japan. Its main product is a solution used by individuals with artificial kidneys. Most individuals in Japan are covered by a national health insurance system. The Japanese government sets the policies for the propor- tion of health care costs covered by the government versus the proportion that is the respon- sibility of the individual. The government also establishes the prices for prescription drugs. The Japanese economy experienced recessionary conditions in recent years. In response to

 

these conditions, the Japanese government increased the proportion of medical costs that is the patient’s responsibility and lowered the prices for prescription drugs. Exhibit 3.30 pre- sents the firm’s balance sheets on March 31 of Year 1 to Year 4, and Exhibit 3.31 presents the firm’s income statements for the years ending March 31, Year 2 to Year 4.

 

 

March 31:

Year 4

Year 3

Year 2

Year 1

ASSETS

 

 

 

 

Cash

Â¥ 6,233

Â¥ 4,569

Â¥ 4,513

Â¥ 5,008

Accounts and notes receivable—Trade

19,003

17,828

19,703

19,457

Inventories

7,693

7,948

8,706

8,607

Deferred income taxes

1,355

1,192

948

824

Prepayments

432

325

640

634

Total Current Assets

Â¥34,716

Â¥31,862

Â¥34,510

Â¥34,530

Investments

3,309

2,356

3,204

4,997

Property, plant, and equipment, at cost

71,792

71,510

71,326

71,018

Less accumulated depreciation

(40,689)

(38,912)

(36,854)

(35,797)

Deferred income taxes

236

1,608

1,481

494

Other assets

4,551

3,904

3,312

3,463

Total Assets

Â¥73,915

Â¥72,328

Â¥76,979

Â¥78,705

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

 

 

Accounts and notes payable—Trade

Â¥10,087

Â¥ 9,629

Â¥10,851

Â¥10,804

Notes payable to banks

10,360

10,328

9,779

10,023

Current portion of long-term debt

100

200

—

—

Other current liabilities

7,200

6,170

9,779

7,565

Total Current Liabilities

Â¥27,747

Â¥26,327

Â¥30,409

Â¥28,392

Long-term debt

8,140

7,889

6,487

8,147

Deferred income taxes

3,361

—

—

—

Employee retirement benefits

809

905

1,087

1,166

Other noncurrent liabilities

175

174

200

216

Total Liabilities

Â¥40,232

Â¥35,295

Â¥38,183

Â¥37,921

Common stock

Â¥10,758

Â¥10,758

Â¥10,758

Â¥10,758

Additional paid-in capital

15,012

15,012

15,012

15,012

Retained earnings

9,179

11,838

13,697

15,014

Accumulated other comprehensive income

(342)

(490)

(659)

—

Treasury stock

(924)

(85)

(12)

—

Total  Shareholders’ Equity

Â¥33,683

Â¥37,033

Â¥38,796

Â¥40,784

Total Liabilities and Shareholders’ Equity

Â¥73,915

Â¥72,328

Â¥76,979

Â¥78,705

                                                                             

 

 

Fuso Pharmaceutical Industries

Income Statements (amounts in millions) (Problem 3.23)

 

Year Ended March 31:

Year 4

Year 3

Year 2

Sales

Cost of goods sold

Â¥41,352 (27,667)

Â¥41,926 (27,850)

Â¥44,226 (28,966)

Selling and administrative expenses

(13,396)

(15,243)

(15,283)

Interest expense

(338)

(364)

(368)

Income tax expense

(1,823)

443

34

Net Income

Â¥(1,872)

Â¥(1,088)

¥   (357)

 

 

 

Required

a.    Prepare a worksheet for the preparation of a statement of cash flows for Fuso Pharmaceutical Industries for each of the years ending March 31, Year 2 to Year 4. Follow the format of Exhibit 3.13 in the text. Notes to the financial statements indi- cate the following:

(1)  The changes in Accumulated Other Comprehensive Income relate to revalu- ations of Investments in Securities to market value. The remaining changes in Investments in Securities result from purchases and sales. Assume that the sales occurred at no gain or loss.

(2)  No sales of property, plant, and equipment took place during the three-year period.

(3)  The changes in Other Noncurrent Assets are investing activities.

(4)  The changes in Employee Retirement Benefits relate to provisions made for retirement benefits net of payments made to retired employees, both of which the statement of cash flows classifies as operating activities.

(5)  The changes in Other Noncurrent Liabilities are financing activities.

b.   Prepare a comparative statement of cash flows for Year 2, Year 3, and Year 4.

c.    Discuss the relation between net income and cash flow from operations and the pat- tern of cash flows from operating, investing, and financing transactions for Year 2, Year 3, and Year 4.

 

 

Answers

(8)
Status NEW Posted 04 Jun 2017 05:06 AM My Price 8.00

-----------

Attachments

file 1496555690-1367349_1_636321348651864503_Cash-flow-estimation.xlsx preview (193 words )
Ma-----------rch----------- 3-----------1:Y-----------ear----------- 4-----------Yea-----------r -----------3Ye-----------arÂ----------- 2Y-----------ear----------- 1-----------Sal-----------esA-----------SSE-----------TSC-----------ost----------- of----------- go-----------ods----------- so-----------ldC-----------ash-----------Sel-----------lin-----------g a-----------nd -----------adm-----------ini-----------str-----------ati-----------ve -----------exp-----------ens-----------esA-----------cco-----------unt-----------s a-----------nd -----------not-----------es -----------rec-----------eiv-----------abl-----------eâ€-----------”Tr-----------ade-----------Int-----------ere-----------st -----------exp-----------ens-----------eIn-----------ven-----------tor-----------ies-----------Inc-----------ome----------- ta-----------x e-----------xpe-----------nse-----------Def-----------err-----------ed -----------inc-----------ome----------- ta-----------xes-----------Net----------- I-----------nco-----------meP-----------rep-----------aym-----------ent-----------sTo-----------tal----------- C-----------urr-----------ent----------- As-----------set-----------sIn-----------ves-----------tme-----------nts-----------Par-----------tic-----------ula-----------rsY-----------ear----------- 2 -----------(Â¥-----------)Ye-----------ar -----------3 (-----------Â¥)-----------Yea-----------r 4----------- (Â-----------¥)P-----------rop-----------ert-----------y, -----------pla-----------nt,----------- an-----------d e-----------qui-----------pme-----------nt,----------- at----------- co-----------stC-----------han-----------ge -----------in -----------ret-----------ain-----------ed -----------ear-----------nin-----------gs -----------inc-----------lud-----------ing----------- de-----------ffe-----------rd -----------tax----------- As-----------set-----------/(L-----------iab-----------lit-----------y)L-----------ess----------- ac-----------cum-----------ula-----------ted-----------
Not Rated(0)